Frankfurt - Delayed Quote EUR

Sandoz Group AG (D8Y0.F)

42.20
+0.40
+(0.96%)
As of 8:02:56 AM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for D8Y0.F

Recent News: D8Y0.F

View More
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
GlobeNewswire yesterday
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
GlobeNewswire 22 days ago
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
GlobeNewswire 23 days ago
Stocks to watch this week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Stocks to watch this week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca
Yahoo Finance UK 27 days ago
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
GlobeNewswire last month
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
GlobeNewswire last month
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
GlobeNewswire last month
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
GlobeNewswire last month
Sandoz reports strong FY 2024 results and Q4 2024 sales

Sandoz reports strong FY 2024 results and Q4 2024 sales
GlobeNewswire 2 months ago
Stocks to watch this week: Broadcom, Costco, JD.com, Adidas and Greggs

Stocks to watch this week: Broadcom, Costco, JD.com, Adidas and Greggs
Yahoo Finance UK 2 months ago
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
GlobeNewswire 2 months ago
View More

Related Tickers

EIIA.F Eisai Co Ltd
5.80
+0.87%
 
INDVl.XC
 
8JM.F Vetoquinol SA
73.90
+0.96%
 
EVT.VI Evotec SE
7.00
-1.10%
 
THEMISMED.BO Themis Medicare Limited
141.10
-1.26%
 
H6D0.F Haleon plc
4.8840
+0.37%
 
ARYX ARYx Therapeutics, Inc.
0.0005
0.00%
 
SBX.BE SynBiotic SE
3.1200
+0.48%
 
TGTR.TA Together Pharma Ltd
396.70
-1.93%
 
LAB.JO Labat Africa Limited
6.00
0.00%